Seizure deterioration in women treated with oxcarbazepine during pregnancy.
Thirteen pregnancies in ten women on oxcarbazepine (OXC) monotherapy and one pregnancy in a woman on OXC and topiramate therapy were retrospectively analyzed. A significant decrease of ratio plasma concentration of 10-monohydroxy derivate (MHD) of oxcarbazepine to dosage was found by 26.2% during first trimester, by 36.5% during second trimester and by 38.2% during third trimester when compared to pre-pregnant levels. Eight patients experienced seizure deterioration during the pregnancy, five of which had been seizure-free before the pregnancy. In seven pregnancies (50%) the seizure frequency was at least doubled during pregnancy compared to a pre-pregnancy baseline. There was a trend toward a correlation between seizure deterioration and decrease in plasma concentration of MHD.
Petrenaite
Vaiva
V
The Epilepsy Clinic, Department of Neurology, Glostrup University Hospital, DK-2600 Glostrup, Denmark. vaivape@gmail.com
Sabers
Anne
A
Hansen-Schwartz
Jacob
J
D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use*; D002220:Carbamazepine / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000078330:Oxcarbazepine; D011247:Pregnancy; D011248:Pregnancy Complications / Q000503:physiopathology*; D011264:Pregnancy Trimesters / Q000097:blood / Q000187:drug effects; D012189:Retrospective Studies; D012640:Seizures / Q000188:drug therapy*
D000927:Anticonvulsants; D002220:Carbamazepine; D000078330:Oxcarbazepine